Zurich-Schlieren, Switzerland, March 23rd, 2022. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today announced that the European Patent Office (EPO) granted a patent covering its lead investigational drug product, TOP-N53 used for the treatment of chronic wounds.
The European patent covers composition of matter for TOP-N53, with a base patent term extending until 2040. This patent provides TOPADUR’s DualTOP™ technology platform with a broader protection, further strengthening the company’s patent portfolio. The patent was already granted in the United States, South Africa, Singapore, Philippines, Mexico, Japan, Israel, China and Australia. TOPADUR anticipates favorable outcomes in other countries as well. This patent application is one of TOPADUR’s multiple patent filings since 2015.
“This is a significant and exciting decision by the EPO, and we view this announcement as recognition of TOPADUR’s important contributions to the field of chronic wounds,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “This patent gives protection to TOP-N53, a first-in-class wound healing drug candidate, which is advancing to Phase 2 clinical trial for the treatment of digital ulcer”, commented Dr. Naef. "If successful, the trial will provide an important validation for our innovative approach to treat debilitating and rare wound healing diseases."
The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.Read more
TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.Read more
The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.Read more